Q-omics provides the consensus-scored FAM3D profile across patient tissues and cancer cell-line models. FAM3D expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAM3D is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, FAM3D RNA expression shows 13,731 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, and TGCT as cancer lineages where FAM3D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM3D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM3D survival associations across molecular data types. FAM3D RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM3D RNA expression–survival associations across cancer types. High FAM3D expression shows unfavorable associations in LGG and ESCA, but favorable associations in HNSC, THCA, KIRC and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FAM3D RNA expression.
This table summarizes FAM3D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM3D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM3D shows lower tumor expression in HNSC, COAD, KICH, BRCA, READ and LUAD. The HNSC box plot shows higher FAM3D RNA expression in normal versus tumor tissue (log2 FC = −5.791, t-test p < 0.001).
This table shows molecular features associated with FAM3D in patient tissues and cancer cell lines. In patient samples, FAM3D shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM3D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
